CL2020001589A1 - Proceso para la preparación de derivados de quinolina. - Google Patents

Proceso para la preparación de derivados de quinolina.

Info

Publication number
CL2020001589A1
CL2020001589A1 CL2020001589A CL2020001589A CL2020001589A1 CL 2020001589 A1 CL2020001589 A1 CL 2020001589A1 CL 2020001589 A CL2020001589 A CL 2020001589A CL 2020001589 A CL2020001589 A CL 2020001589A CL 2020001589 A1 CL2020001589 A1 CL 2020001589A1
Authority
CL
Chile
Prior art keywords
preparation
quinoline derivatives
new process
well
compounds
Prior art date
Application number
CL2020001589A
Other languages
English (en)
Inventor
ERVER Florian
Memmel Frank
Himmler Thomas
Karl Steib Andreas
Nowakowski Marc
Original Assignee
Bayer Animal Health Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Animal Health Gmbh filed Critical Bayer Animal Health Gmbh
Publication of CL2020001589A1 publication Critical patent/CL2020001589A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J23/00—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00
    • B01J23/38—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00 of noble metals
    • B01J23/40—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00 of noble metals of the platinum group metals
    • B01J23/44—Palladium
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4

Abstract

La presente invención se refiere a un nuevo proceso para preparar compuestos de quinolina de la fórmula general (II): (II), en la cual Q, A, R4, R3 y R3’ son como se definen en el presente, así como los compuestos intermedios de dicho nuevo proceso. (II), en la cual Q, A, R4, R3 y R3’ son como se definen en el presente, así como los compuestos intermedios de dicho nuevo proceso.
CL2020001589A 2017-12-15 2020-06-12 Proceso para la preparación de derivados de quinolina. CL2020001589A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP17207586 2017-12-15

Publications (1)

Publication Number Publication Date
CL2020001589A1 true CL2020001589A1 (es) 2020-11-20

Family

ID=60673654

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2020001589A CL2020001589A1 (es) 2017-12-15 2020-06-12 Proceso para la preparación de derivados de quinolina.

Country Status (18)

Country Link
US (1) US11505544B2 (es)
EP (1) EP3692037A1 (es)
JP (1) JP2021506774A (es)
KR (1) KR20200099548A (es)
CN (1) CN111448192B (es)
AU (1) AU2018382999B2 (es)
BR (1) BR112020011901A2 (es)
CA (1) CA3085675A1 (es)
CL (1) CL2020001589A1 (es)
CO (1) CO2020007222A2 (es)
DO (1) DOP2020000118A (es)
IL (1) IL275216A (es)
MX (1) MX2020006185A (es)
PH (1) PH12020550905A1 (es)
SG (1) SG11202004260YA (es)
TW (1) TWI809018B (es)
UY (1) UY38009A (es)
WO (1) WO2019115768A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CR20210477A (es) 2019-03-19 2022-01-06 Boehringer Ingelheim Animal Health Usa Inc Compuestos de aza-benzotiofeno y aza-benzofurano como antihelmínticos
CA3179528A1 (en) * 2020-04-09 2021-10-14 Bayer Animal Health Gmbh Substituted condensed azines as anthelmintic compounds
CN116249704A (zh) 2020-05-29 2023-06-09 勃林格殷格翰动物保健美国公司 驱虫用杂环化合物
EP4148052A1 (en) * 2021-09-09 2023-03-15 Bayer Animal Health GmbH New quinoline derivatives
US20230159543A1 (en) 2021-11-01 2023-05-25 Boehringer Ingelheim Vetmedica Gmbh Anthelmintic pyrrolopyridazine compounds

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0101999A3 (en) * 1997-12-22 2003-06-30 Upjohn Co 4-hydroxyquinoline-3-carboxamides and hydrazides use of them and pharmaceutical compositions containing them
CA2395772C (en) 1999-12-28 2010-09-28 Eisai Co., Ltd. Sulfonamide-containing heterocyclic compounds
CN100356979C (zh) 2000-02-03 2007-12-26 卫材R&D管理有限公司 整联蛋白表达抑制剂
JP2008214323A (ja) 2007-03-08 2008-09-18 Kyowa Hakko Kogyo Co Ltd 皮膚疾患の治療及び／または予防剤
US9006257B2 (en) 2012-02-09 2015-04-14 Glenmark Pharmaceuticals S.A. Bicyclic compounds as mPGES-1 inhibitors
AR098475A1 (es) * 2013-11-26 2016-06-01 Bayer Cropscience Ag Compuestos pesticidas y usos
PE20170331A1 (es) * 2014-03-24 2017-04-28 Guangdong Zhongsheng Pharmaceutical Co Ltd Derivados quinolina como inhibidores smo
BR112018012469B1 (pt) 2015-12-17 2020-11-24 Astex Therapeutics Limited compostos quinolina-3-carboxamidas como inibidores da h-pgds, composição farmacêutica compreendendo os ditos compostos e uso terapêutico dos mesmos.
EP3538512B1 (en) * 2016-11-11 2021-06-16 Bayer Animal Health GmbH New anthelmintic quinoline-3-carboxamide derivatives

Also Published As

Publication number Publication date
KR20200099548A (ko) 2020-08-24
TW201927773A (zh) 2019-07-16
CN111448192A (zh) 2020-07-24
RU2020123282A (ru) 2022-01-17
US20200308153A1 (en) 2020-10-01
PH12020550905A1 (en) 2021-05-17
SG11202004260YA (en) 2020-06-29
AU2018382999A1 (en) 2020-05-28
BR112020011901A2 (pt) 2020-11-24
IL275216A (en) 2020-07-30
CA3085675A1 (en) 2019-06-20
US11505544B2 (en) 2022-11-22
WO2019115768A1 (en) 2019-06-20
TWI809018B (zh) 2023-07-21
DOP2020000118A (es) 2020-08-31
CN111448192B (zh) 2024-04-12
JP2021506774A (ja) 2021-02-22
UY38009A (es) 2019-07-31
AU2018382999B2 (en) 2023-11-23
CO2020007222A2 (es) 2020-11-20
EP3692037A1 (en) 2020-08-12
MX2020006185A (es) 2020-09-03

Similar Documents

Publication Publication Date Title
CL2020001589A1 (es) Proceso para la preparación de derivados de quinolina.
CL2020003007A1 (es) Lactamas biciclicas y metodos de uso de las mismas (divisional solicitud no. 3486-2017)
CY1121395T1 (el) Τετραϋδροπυριδοπυραζινες-διαμορφωτες toy gpr6
CO2017008600A2 (es) Análogos de desacetoxitubulisina h, composiciones y método de producción de los mismos
MD3464249T2 (ro) Derivați carbonucleozidici substituiţi utili în calitate de agenți anticanceroşi
PH12015500263A1 (en) New bicyclic derivatives
PE20181145A1 (es) Compuestos de piridina
EA201890752A1 (ru) Способ получения противогрибковых соединений
MA38982A1 (fr) Nouvel octahydro-cyclobuta [1,2-c; 3,4-c'] dipyrrol-2-yl
UY34955A (es) 4-metil-2,3,5,9,9b-pentaaza-ciclopenta[a]naftalenos
MX2016007128A (es) Compuestos del receptor 6 de quimiocina (ccr6).
BR112013018732A2 (pt) novos derivados de amida de aril-benzocicloalquila
EA201791096A1 (ru) 4-оксо-3,4-дигидро-1,2,3-бензотриазины в качестве модуляторов gpr139
EA201791058A1 (ru) Морфолин- и 1,4-оксазепан-амиды в качестве агонистов соматостатинового рецептора подтипа 4 (sstr4)
CU24608B1 (es) Compuestos de dihidrooxadiazinonas sustituidas útiles en el tratamiento de enfermedades hiperproliferativas y métodos para preparar dichos compuestos
CO2020002396A2 (es) Nuevos compuestos heterocíclicos fungicidas
BR112016029510A2 (pt) métodos para a preparação de um composto, e, composto intermediário.
UY37932A (es) Proceso para producir compuestos de piridazinona herbicidas
DOP2016000211A (es) Pirazinas moduladoras de gpr6
CL2018000856A1 (es) Derivados de éter cíclico de pirazolo[1,5-a]pirimidin-3-carboxiamida.
CU24518B1 (es) Derivados sustituidos de 6-(1h-pirazol-1-il)pirimidin-4-amina
AR101951A1 (es) Síntesis de ent-progesterona e intermediarios de la misma
EA201992360A1 (ru) Кристаллические формы (s)-афоксоланера
MX2018009544A (es) Metodo para preparar derivados de 4-aminoindano sustituido.
ES2670477R1 (es) Procedimiento para la preparacion de la 17beta-hidroxi-des-a-androst-9,10-en-5-ona